Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Systematic Reviews
Published in: Systematic Reviews 1/2022

Open Access 01-12-2022 | Praziquantel | Research

Patient journey and resources mapping to implement a praziquantel mass drug administration program for children aged 5 years and below in resource-limited settings

Authors: Mhlengi Vella Ncube, Muhubiri Kabuyaya, Moses John Chimbari

Published in: Systematic Reviews | Issue 1/2022

Login to get access

Abstract

Background

The early childhood development of millions of children in some low- and medium-income countries may be compromised by schistosomiasis infections contracted at the age of 5 years and below. Currently, there are no standard guidelines for treating schistosomiasis in children that are 5 years and younger using praziquantel (PZQ), the only drug that the World Health Organization (WHO) recommends for treating schistosomiasis. The review is on processes and resources involved in the treatment of schistosomiasis in children aged 5 years and below.

Methods

An electronic search for peer-reviewed articles published in the period from January 2011 to August 2021 was done in the Academic Search Complete, CINAHL with Full Text, Health Source: Nursing/Academic Edition, and MEDLINE databases via EBSCOHost and Google Scholar databases. The search targeted journals that described the treatment of schistosomiasis in children 5 years and below using praziquantel.

Results

Thirteen studies met the inclusion criteria. The patient journey for treating schistosomiasis in children aged 5 years old and below using PZQ included the following activities: enrolment of the children into the treatment program; clinical examination; diagnosis; taking anthropometric measurements; feeding the children, making the PZQ palatable to the children; administration of PZQ; and monitoring of side effects. There was also a variation in the resources used to treat children aged 5 and below for schistosomiasis.

Conclusions

A PZQ mass drug administration program for children aged 5 years old and below in endemic areas should exclude the diagnosis of schistosomiasis before treatment. The resources required in the treatment process should be affordable, and should not require skills and maintenance resources that are beyond those that are available at the primary healthcare level.
Appendix
Available only for authorised users
Literature
1.
Mo AX, Agosti JM, Walson JL, Hall BF, Gordon L. Schistosomiasis elimination strategies and potential role of a vaccine in achieving global health goals. Am J Trop Med Hyg. 2014;90(1):54–60.PubMedPubMedCentralCrossRef
2.
Ross AG, Olveda RM, Chy D, Olveda DU, Li Y, Harn DA, et al. Can mass drug administration lead to the sustainable control of schistosomiasis? J Infect Dis. 2014;211(2):283–9.PubMedCrossRef
3.
Olveda DU, McManus DP, Ross AG. Mass drug administration and the global control of schistosomiasis: successes, limitations and clinical outcomes. Curr Opin Infect Dis. 2016;29(6):595–608.PubMedCrossRef
4.
5.
French MD, Evans D, Fleming FM, Secor WE, Biritwum N-K, Brooker SJ, et al. Schistosomiasis in Africa: improving strategies for long-term and sustainable morbidity control. PLoS Negl Trop Dis. 2018;12(6):e0006484.PubMedPubMedCentralCrossRef
6.
WHO. Schistosomiasis and soil-transmitted helminthiases: number of people treated in 2016. Wkly Epidemiol Rec 749-760. 2017;49:749–60.
7.
Adenowo AF, Oyinloye BE, Ogunyinka BI, Kappo AP. Impact of human schistosomiasis in sub-Saharan Africa. Brazilian J Infect Dis. 2015;19:196–205.CrossRef
8.
Dabo A, Bary B, Kouriba B, Sankaré O, Doumbo O. Factors associated with coverage of praziquantel for schistosomiasis control in the community-direct intervention (CDI) approach in Mali (West Africa). Infect Dis Poverty. 2013;2(1):11.PubMedPubMedCentralCrossRef
9.
10.
Stothard JR, Sousa-Figueiredo JC, Betson M, Green HK, Seto EYW, Garba A, et al. Closing the praziquantel treatment gap: new steps in epidemiological monitoring and control of schistosomiasis in African infants and preschool-aged children. Parasitology. 2011;138(12):1593–606.PubMedCrossRef
11.
Osakunor DNM, Mduluza T, Midzi N, Chase-Topping M, Mutsaka-Makuvaza MJ, Chimponda T, et al. Dynamics of paediatric urogenital schistosome infection, morbidity and treatment: a longitudinal study among preschool children in Zimbabwe. BMJ Glob Health. 2018;3(2):e000661.PubMedPubMedCentralCrossRef
12.
Stothard JR, Sousa-Figueiredo JC, Betson M, Bustinduy A, Reinhard-Rupp J. Schistosomiasis in African infants and preschool children: let them now be treated! Trends Parasitol. 2013;29(4):197–205.PubMedPubMedCentralCrossRef
13.
Navaratnam AMD, Sousa-Figueiredo JC, Stothard JR, Kabatereine NB, Fenwick A, Mutumba-Nakalembe MJ. Efficacy of praziquantel syrup versus crushed praziquantel tablets in the treatment of intestinal schistosomiasis in Ugandan preschool children, with observation on compliance and safety. Trans R Soc Trop Med Hyg. 2012;106(7):400–7.PubMedCrossRef
14.
Garba A, Lamine MS, Djibo A, Tahirou A, Aouami MA, Alfari A, et al. Safety and efficacy of praziquantel syrup (Epiquantel®) against Schistosoma haematobium and Schistosoma mansoni in preschool-aged children in Niger. Acta Trop. 2013;128(2):318–25.PubMedCrossRef
15.
16.
Sousa-Figueiredo JC, Betson M, Stothard JR. Treatment of schistosomiasis in African infants and preschool-aged children: downward extension and biometric optimization of the current praziquantel dose pole. Int Health. 2012;4(2):95–102.PubMedCrossRef
17.
18.
Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol. 2018;18(1):143-.PubMedPubMedCentralCrossRef
19.
Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19–32.
20.
Levac D, Colquhoun H, O’Brien KK. Scoping studies: advancing the methodology. Implementation Sci. 2010;5:69-.
21.
22.
23.
Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D. PRISMA extension for scoping reviews (PRISMAScR): checklist and explanation. Ann Intern Med. 2018;169:467–73.
24.
Amin M, Swar M, Kardaman M, Elhussein D, Nouman G, Mahmoud A, et al. Treatment of pre-school children under 6 years of age for schistosomiasis: safety, efficacy and acceptability of praziquantel. Sudan J Med Sci. 2012;7(2):67–76.
25.
Coulibaly JT, N’Gbesso YK, Knopp S, Keiser J, N’Goran EK, Utzinger J. Efficacy and safety of praziquantel in preschool-aged children in an area co-endemic for Schistosoma mansoni and S. haematobium. PLoS Negl Trop Dis. 2012;6(12):e1917.
26.
Coulibaly JT, Panic G, Silué KD, Kovač J, Hattendorf J, Keiser J. Efficacy and safety of praziquantel in preschool-aged and school-aged children infected with Schistosoma mansoni: a randomised controlled, parallel-group, dose-ranging, phase 2 trial. Lancet Glob Health. 2017;5(7):e688–98.PubMedPubMedCentralCrossRef
27.
Coulibaly JT, Panic G, Yapi RB, Kovač J, Barda B, N’Gbesso YK, et al. Efficacy and safety of ascending doses of praziquantel against Schistosoma haematobium infection in preschool-aged and school-aged children: a single-blind randomised controlled trial. BMC Med. 2018;16(1):81.PubMedPubMedCentralCrossRef
28.
Coulibaly JT, Panic G, Yapi RB, Kovač J, Barda B, N’Gbesso YK, et al. Efficacy and safety of ascending doses of praziquantel against Schistosoma haematobium infection in preschool-aged and school-aged children: a single-blind randomised controlled trial. BMC Med. 2018;16(1):1–10.CrossRef
29.
Mutapi F, Rujeni N, Bourke C, Mitchell K, Appleby L, Nausch N, et al. Schistosoma haematobium treatment in 1–5 year old children: safety and efficacy of the antihelminthic drug praziquantel. PLoS Negl Trop Dis. 2011;5(5):e1143.PubMedPubMedCentralCrossRef
30.
Nalugwa A, Nuwaha F, Tukahebwa EM, Olsen A. Single versus double dose praziquantel comparison on efficacy and Schistosoma mansoni re-infection in preschool-age children in Uganda: a randomized controlled trial. Plos Negl Trop Dis. 2015;9(5):e0003796-e.CrossRef
31.
Namwanje H, Kabatereine NB, Olsen A. The acceptability and safety of praziquantel alone and in combination with mebendazole in the treatment of Schistosoma mansoni and soil-transmitted helminthiasis in children aged 1–4 years in Uganda. Parasitology. 2011;138(12):1586–92.PubMedCrossRef
32.
Sousa-Figueiredo JC, Pleasant J, Day M, Betson M, Rollinson D, Montresor A, et al. Treatment of intestinal schistosomiasis in Ugandan preschool children: best diagnosis, treatment efficacy and side-effects, and an extended praziquantel dosing pole. Int Health. 2010;2(2):103–13.PubMedCrossRef
33.
Wami WM, Nausch N, Midzi N, Gwisai R, Mduluza T, Woolhouse MEJ, et al. Comparative assessment of health benefits of praziquantel treatment of urogenital schistosomiasis in preschool and primary school-aged children. Biomed Res Int. 2016;2016:9162631-.PubMedPubMedCentralCrossRef
34.
Sousa-Figueiredo J, Betson M, Atuhaire A, Arinaitwe M, Navaratnam A. Performance and safety of praziquantel for treatment of intestinal schistosomiasis in infants and preschool children. PLoS Negl Trop Dis. 2012;6(10):e1864.PubMedPubMedCentralCrossRef
35.
Garba A, Barkiré N, Djibo A, Lamine MS, Sofo B, Gouvras AN, et al. Schistosomiasis in infants and preschool-aged children: infection in a single Schistosoma haematobium and a mixed S. haematobium–S. mansoni foci of Niger. Acta Tropica. 2010;115(3):212–9.PubMedCrossRef
36.
Davis PS, Schul PL. Addressing the contingent effects of business unit strategic orientation on relationships between organizational context and business unit performance. J Bus Res. 1993;27(3):183–200.CrossRef
37.
Olveda RM, Acosta LP, Tallo V, Baltazar PI, Lesiguez JLS, Estanislao GG, et al. Efficacy and safety of praziquantel for the treatment of human schistosomiasis during pregnancy: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2016;16(2):199–208.PubMedCrossRef
38.
Martin DL, Bid R, Sandi F, Goodhew EB, Massae PA, Lasway A, et al. Serology for trachoma surveillance after cessation of mass drug administration. PLoS Negl Trop Dis. 2015;9(2):e0003555.PubMedPubMedCentralCrossRef
39.
South African Department of Health. South Africa National Master Plan for the Elimination of Neglected Tropical Diseases (2019 - 2025). South African Department of Health; 2019.
40.
Betson M, Sousa-Figueiredo JC, Rowell C, Kabatereine NB, Stothard JR. Intestinal schistosomiasis in mothers and young children in Uganda: investigation of field-applicable markers of bowel morbidity. Am J Trop Med Hyg. 2010;83(5):1048–55.PubMedPubMedCentralCrossRef
41.
Avinash B, Avinash B, Shivalinga B, Jyothikiran S, Padmini M. Going green with eco-friendly dentistry. J Contemp Dent Pract. 2013;14(4):766.PubMedCrossRef
42.
Dickinson FM, McCauley M, Madaj B, van den Broek N. Using electronic tablets for data collection for healthcare service and maternal health assessments in low resource settings: lessons learnt. BMC Health Serv Res. 2019;19(1):336.PubMedPubMedCentralCrossRef
43.
Turner HC, Toor J, Déirdre Hollingsworth T, Anderson RM. Economic evaluations of mass drug administration: the importance of economies of scale and scope. Clin Infect Dis. 2017;66(8):1298–303.PubMedCentralCrossRef
44.
King C, Hall J, Banda M, Beard J, Bird J, Kazembe P, et al. Electronic data capture in a rural African setting: evaluating experiences with different systems in Malawi. Glob Health Action. 2014;7(1):25878.PubMedCrossRef
45.
Ochodo EA, Spek B, Reitsma JB, Van Lieshout L, Polman K, Lamberton P, et al. Rapid screening and diagnostic tests for human schistosomiasis in endemic areas. Cochrane Database Syst Rev. 2012(2).
46.
Sousa-Figueiredo JC, Betson M, Kabatereine NB, Stothard JR. The urine circulating cathodic antigen (CCA) dipstick: a valid substitute for microscopy for mapping and point-of-care diagnosis of intestinal schistosomiasis. PLoS Negl Trop Dis. 2013;7(1):e2008.PubMedPubMedCentralCrossRef
47.
Utzinger J, Becker SL, van Lieshout L, van Dam GJ, Knopp S. New diagnostic tools in schistosomiasis. Clin Microbiol Infect. 2015;21(6):529–42.PubMedCrossRef
48.
Mutapi F. Changing policy and practice in the control of pediatric schistosomiasis. Pediatrics. 2015;135(3):536–44.PubMedCrossRef
49.
Olliaro PL, Vaillant M, Hayes DJ, Montresor A, Chitsulo L. Practical dosing of praziquantel for schistosomiasis in preschool-aged children. Tropical Med Int Health. 2013;18(9):1085–9.CrossRef
50.
Leyvraz M, Mizéhoun-Adissoda C, Houinato D, Moussa Baldé N, Damasceno A, Viswanathan B, et al. Food consumption, knowledge, attitudes, and practices related to salt in urban areas in five sub-Saharan African countries. Nutrients. 2018;10(8):1028.PubMedCentralCrossRef
51.
Matilsky DK, Maleta K, Castleman T, Manary MJ. Supplementary feeding with fortified spreads results in higher recovery rates than with a corn/soy blend in moderately wasted children. J Nutr. 2009;139(4):773–8.PubMedPubMedCentralCrossRef
52.
Bunupuradah T, Wannachai S, Chuamchaitrakool A, Intasan J, Nuchapong T, Neiss W, et al. Use of taste-masking product, FLAVORx, to assist Thai children to ingest generic antiretrovirals. AIDS Res Ther. 2006;3(1):30.PubMedPubMedCentralCrossRef
53.
Bulusu S, Laviolette L, Mannar V, Reddy V. Cereal fortification programs in developing countries. Issues in Complementary Feeding. 60: Karger Publishers; 2007. p. 91–105.
54.
Frigerio S, Macario M, Iacovone G, Dussey-Comlavi KJ, Narcisi P, Ndiaye AT, et al. Schistosoma haematobium infection, health and nutritional status in school-age children in a rural setting in northern Senegal. Minerva Pediatr. 2016;68(4):282–7.PubMed
55.
56.
Burnim M, Ivy JA, King CH. Systematic review of community-based, school-based, and combined delivery modes for reaching school-aged children in mass drug administration programs for schistosomiasis. PLoS Negl Trop Dis. 2017;11(10):e0006043.PubMedPubMedCentralCrossRef
57.
Blevins J, Kiser M, Lemon E, Kone A. The percentage of HIV treatment and prevention services in Kenya provided by faith-based health providers. Dev Pract. 2017;27(5):646–57.CrossRef
58.
Berra K, Franklin B, Jennings C. Community-based healthy living interventions. Prog Cardiovasc Dis. 2017;59(5):430–9.PubMedCrossRef
59.
Peterson J, Atwood JR, Yates B. Key elements for church-based health promotion programs: outcome-based literature review. Public Health Nurs. 2002;19(6):401–11.PubMedCrossRef
60.
King R, Warsi S, Amos A, Shah S, Mir G, Sheikh A, et al. Involving mosques in health promotion programmes: a qualitative exploration of the MCLASS intervention on smoking in the home. Health Educ Res. 2017;32(4):293–305.PubMedPubMedCentralCrossRef
61.
Coulibaly Y, Cavalli A, Van Dormael M, Polman K, Kegels G. Programme activities: a major burden for district health systems? Tropical Med Int Health. 2008;13(12):1430–2.CrossRef
62.
Janssen N, Ndirangu J, Newell M-L, Bland R. Successful paediatric HIV treatment in rural primary care in Africa. Arch Dis Child. 2010;95(6):414–21.PubMedCrossRef
63.
Nandha B, Sadanandane C, Jambulingam P, Das PK. Delivery strategy of mass annual single dose DEC administration to eliminate lymphatic filariasis in the urban areas of Pondicherry, South India: 5 years of experience. Filaria J. 2007;6(1):7.PubMedPubMedCentralCrossRef
64.
Dean L, Page S, Hawkins K, Stothard R, Thomson R, Wanji S, et al. Tailoring mass drug administration to context: implementation research is critical in achieving equitable progress in the control and elimination of helminth neglected tropical diseases in sub-Saharan Africa. Int Health. 2016;8(4):233–4.PubMedCrossRef
65.
Hodges MH, Sonnie M, Turay H, Conteh A, MacCarthy F, Sesay S. Maintaining effective mass drug administration for lymphatic filariasis through in-process monitoring in Sierra Leone. Parasit Vectors. 2012;5(1):232.PubMedPubMedCentralCrossRef
66.
Kemal M, Tadesse G, Esmael A, Abay SM, Kebede T. Schistosoma mansoni infection among preschool age children attending Erer Health Center, Ethiopia and the response rate to praziquantel. BMC research notes. 2019;12(1):1–6.
Metadata
Title
Patient journey and resources mapping to implement a praziquantel mass drug administration program for children aged 5 years and below in resource-limited settings
Authors
Mhlengi Vella Ncube
Muhubiri Kabuyaya
Moses John Chimbari
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Systematic Reviews / Issue 1/2022
Electronic ISSN: 2046-4053
DOI
https://doi.org/10.1186/s13643-022-02087-z

Other articles of this Issue 1/2022

Systematic Reviews 1/2022 Go to the issue

Research

Instruments to assess the role of the clinical pharmacist: a systematic review

Protocol

Spatial and spatio-temporal epidemiological approaches to inform COVID-19 surveillance and control: a review protocol

Commentary

The evidence synthesis and meta-analysis in R conference (ESMARConf): levelling the playing field of conference accessibility and equitability

Research

Quality of life and complications after nephron-sparing treatment of renal cell carcinoma stage T1—a systematic review

Protocol

Evaluation of efficacy and safety of intradermal delivery of vaccines through microneedle(s) in human beings: a protocol for a systematic review

Research

Peer support for carers and patients with inflammatory bowel disease: a systematic review